T1	Participants 42 80	patients with hepatocellular carcinoma
T2	Participants 293 312	Forty-five patients
T3	Participants 380 408	patients to treatment (n=21)
T4	Participants 412 432	control group (n=24)
T5	Participants 478 493	treatment group
T6	Participants 572 580	patients
T7	Participants 779 794	7 cases (33.3%)
T8	Participants 823 839	12 cases (50.0%)
T9	Participants 1096 1106	two groups
T10	Participants 1162 1177	treatment group
